Investors

Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.

We currently have 28 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.9 billion (IQVIA, February 2018).

We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.

"As we execute our strategy, our focus is to scale up and strengthen our business, so we can deliver sustained financial performance."

Damian Finio
CFO

Recent News

Teligent, Inc. Announces FDA Approval of Fluocinonide Ointment USP, 0.05%

BUENA, N.J., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharm...

Learn More

Teligent Secures Critical Supply during Canadian National Drug Crisis despite Worldwide Shortage

TORONTO , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ:TLGT) (“Teligent”), a specialty generic pharmaceutic...

Learn More

Teligent, Inc. Announces Second Quarter 2018 Results

BUENA, N.J. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic phar...

Learn More

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.


Investor Overview